

CORhum - Morbidity-mortality of COVID-19 in patients with chronic rheumatic disorder treated with immunosuppressants

Head :LETAROUILLY Jean-Guillaume

Last update : 05/05/2021 | Version : 1 | ID : 73495

General	
Identification	
Detailed name	Morbidity-mortality of COVID-19 in patients with chronic rheumatic disorder treated with immunosuppressants
Sign or acronym	CORhum
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL 2021796 v 0, CPP CPP2020-06-056b, NCT04426279
General Aspects	
Medical area	Internal medicine Rheumatology
Study in connection with Covid-19	Yes
Pathology (details)	systemic lupus erythematosus, spondyloarthritis, rheumatoid arthritis
Keywords	systemic lupus erythematosus, spondyloarthritis, chronic rheumatic disorder, biological therapy, rheumatoid arthritis, immunosuppressants
Scientific investigator(s) (Contact)	
Name of the director	LETAROUILLY
Surname	Jean-Guillaume
Address	Service de Rhumatologie Hôpital Roger Salengro Rue Emile Laine 59037 Lille
Phone	320446926
Email	jeanguillaume.letarouilly@chu-lille.fr

Organization	Lille University Hospital
Collaborations	
Participation in projects, networks and consortia	Yes
Funding	
Governance of the database	
Sponsor(s) or organisation(s) responsible	Lille University Hospital
Organisation status	Public
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is carried out as part of an interventional study	No
Database objective	
Main objective	Estimate morbidity-mortality associated with COVID-19 in patients with chronic rheumatic disorder (CRD) receiving immunosuppressants (IS).
Inclusion criteria	Patients with RA on csDMARD +/- bDMARD or tsDMARD +/- corticosteroid therapy fulfilling 2010 ACR/EULAR classification criteria? Patients with SpA receiving bDMARD or tsDMARD +/- csDMARD +/- non-steroidal anti-inflammatory drugs fulfilling ASAS classification criteria? Patients with SLE receiving hydroxychloroquine +/- csDMARD +/- corticosteroid therapy +/- bDMARD fulfilling 2019 ACR/EULAR classification criteria
Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years)

Population covered	Sick population
Pathology	L93 - Lupus erythematosus
	M05-M14 - Inflammatory polyarthropathies
Gender	Male Woman
Geography area	Local
French regions covered by the database	Nord - Pas-de-Calais Picardie
Data collection	
Dates	
Size of the database	
Size of the database (number of individuals)	[500-1000[individuals
Details of the number of individuals	1500
Data	
Database activity	Current data collection
Type of data collected	Clinical data
Presence of a biobank	No
Procedures	
Followed pathology	
Promotion and access	
Promotion	
Access	